Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy

Barrett Esophagus Clinical Trial

Official title:

Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02994693
• Other study ID #: 2016-P000919
• Secondary ID: 5R01CA184102-02
• Status: Recruiting
• Start date: December 2016
• Est. completion date: December 2024

Study information

• Verified date: January 2023
• Source: Massachusetts General Hospital
• Contact: Anna Gao, RN
• Phone: 617-643-6092
• Email: Tearneylabtrials[@]partners.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this research is to determine the natural history of Barrett's esophagus (BE) using tethered capsule endomicroscopy (TCE) in patients undergoing surveillance endoscopy.

Description:

The MGH will be the first site in the multi-center study to begin enrolling. At the MGH 100 subjects with a previous diagnosis of Barrett's Esophagus (BE) will be enrolled. Each subject will undergo a minimum of 2 esophagogastroduodenoscopies (EGD), one around the time of inclusion into the study and one at the end of the study, and 4 TCE imaging sessions (baseline, 1-year, 2-years and at the end of the 3-years follow-up). If it is determined by the treating physician that additional EGDs are needed, for extended follow-up or treatment, capsule imaging will be performed whenever possible. Patients will have received written information prior to the day of the capsule procedure and patients will have another chance to discuss the procedure with the study coordinator and clinical study staff during the consent process prior to the capsule procedure. Participation in this study is completely voluntary, and the patient can stop the procedure at any time. For each of the imaged patients, inclusion criteria and clinical characteristics such as age, sex, body mass index (BMI), current medication regimen, smoking history and GI related history will be recorded in the clinical form. Subjects will be seated and asked to sip water to facilitate swallowing the capsule. The device will be operated by experienced study staff trained in the procedure such as a registered nurse or one of the endoscopist co-investigators in this study. Emergency phone and/or pager contact of the collaborating GI clinician(s) will be provided. They will also be accessible during the procedure if any problems are encountered that require their expertise. Imaging will be performed in the same manner as in our other current IRB approved tethered capsule endomicroscopy studies. The capsule position will be controlled manually via the tether outside of the subject's mouth by the catheter operator. Recorded real-time cross-sectional images displayed on the monitor and distance marks on the tether will be used for confirmation of capsule position in the esophagus. Images will be viewed in real time to determine when the capsule has reached the stomach. The resistance of the tether can also give information of the cardia position. Once in the stomach, the capsule will be gradually pulled back up through the esophagus to the mouth, also while imaging. The capsule may be repositioned for imaging up to 4 times up and 4 times down the esophagus. The subject may be asked to swallow a different size capsule (ranging from 5-12.8 mm in diameter and 20-30 cm in length) to obtain the best distal esophageal images. It is expected that the maximum experimental time including swallowing the capsule, the imaging procedure, and removal of the capsule will take approximately 10 minutes in total.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with known BE without high grade dysplasia, intramucosal adenocarcinoma or esophageal adenocarcinoma, confirmed by endoscopic biopsy,
• Patients over the age of 18
• Patients who are capable of giving informed consent
• Patients who had or will have a standard of care EGD within 9 to 15 months
• Subjects must have no solid food for at least 4 hours prior to the procedure, and only clear liquids for 2 hours prior to the procedure.

Exclusion Criteria:

• Patients with prior endoscopic ablation or resection treatment of BE
• Patients with esophageal fistula and/or esophageal strictures with a luminal stricture diameter that is smaller than the diameter of the capsule
• Patients with the inability to swallow capsules.
• Pregnancy, according to patient information

Related Conditions & MeSH terms

• Barrett Esophagus
• Barretts Esophagus With Dysplasia

Intervention

Device:
• OFDI capsule imaging
Imaging of Barrett's esophagus (BE) using OFDI capsule imaging

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Massachusetts General Hospital	National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Longitudinal assessment of the Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy	An investigator will assess the quality of the recorded images and movies obtained with each exam after imaging has been completed. They will assess how the images change over time.	Approximate 25 minutes visit (10 min image acquisition)